

ASX ANNOUNCEMENT

20 July 2020

**Respiri Signs Agreement with BNPL Provider ZIP – update**

**Respiri Limited (ASX:RSH) (“Respiri” or the “Company”)**, an eHealth SaaS Company supporting respiratory health management, was pleased to announce this morning that it has executed a merchant services agreement with a leading Buy Now Pay Later (BNPL) provider Zip Money Payments Pty Ltd, a wholly owned subsidiary of Zip Co Limited (ASX:Z1P).

Further to this announcement the Company would like to clarify the importance of this agreement and its significance to the imminent release of the Company’s revenue guidance.

The Zip agreement enables Respiri consumers to purchase wheezo® and pay over six interest-free monthly instalments. The availability of this payment plan option removes a potential barrier for a portion of our target customer base. As a result we expect higher customer uptake resulting in higher forecast revenues.

By taking advantage of the ZIP agreement customers will pay \$14 per week (including SaaS subscription) for a period of six months rather than an upfront price for device-only of \$299. Based on prior experience of similar offerings the impact of such a facility is expected to be an additional 10% in revenue over and above other channels.

Respiri’s mission is help improve the quality of life of all asthma sufferers and the Company is committed to ensuring wheezo® is available in a timely fashion to all customers.

The Company expects to provide revenue guidance for the 2021 calendar year within the next 5 business days.

- ENDS -

For further information, investors and media please contact:

**Mr Marjan Mikel**  
 CEO & Managing Director  
 Respiri Limited  
 P: +61 408 462 873  
 E: [marjan@respiri.co](mailto:marjan@respiri.co)

**Mr Nicholas Smedley**  
 Executive Chairman  
 Respiri Limited  
 P: +61 447 074 160  
 E: [nicholas@respiri.co](mailto:nicholas@respiri.co)

*This ASX announcement dated 20 July 2020 has been authorised for release by the Board of Directors of Respiri Limited.*

## About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit [www.respi.co](http://www.respi.co)

## Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.